Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast07 HER2-positive Metastatic Breast Cancer Combinations
2023-505309-18-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan in HER2-enriched breast cancer (HER2+) (4 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability (Part 1) and Safety and tolerability (Part 2). Planned start Jan 2021; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2023-505309-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505309-18-00.